Form 4: Enveric Biosciences Director Frank Pasqualone Reports Changes in Beneficial Ownership

Frank Pasqualone, a director at Enveric Biosciences, reported the acquisition and disposal of common stock related to a restricted stock grant.

Summary

• On October 9, 2024, Frank Pasqualone, a director of Enveric Biosciences, Inc., filed a Form 4 to report changes in beneficial ownership.
• Pasqualone acquired 47,733 shares of common stock at $0, and disposed of 1,000 shares.
• Following the transaction, Pasqualone beneficially owns 48,733 shares of Enveric Biosciences common stock.
• The acquisition of shares represents restricted stock granted under the company's 2020 Long-Term Incentive Plan, as amended.
• These shares will vest in full on December 31, 2024, subject to the terms of the plan and the restricted stock award agreement.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The grant of restricted stock to a director aligns their interests with the long-term success of the company.
• The vesting of the shares on December 31, 2024, provides an incentive for continued service and contribution.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the holdings of a director at Enveric Biosciences.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects changes in insider ownership.
• The grant of restricted stock incentivizes the director, potentially benefiting the company and its stakeholders.

Key Dates

Keywords

Form 4, beneficial ownership, Enveric Biosciences, restricted stock, director, ENVB, Pasqualone